Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
COLUMN
When Leading Teams, Focus on the Principles, Not the Personalities
Philip Carrigan According to a survey reported by the Harvard Business Review (HBR) in June 2015, 75% of cross-functional teams are dysfunctional. The HBR report concluded that most cross-functional teams fail on at least three of five criteria: (1) meeting…
To read the full story
COLUMN
- Japan’s Healthcare Pulse: An 18-Month Market Snapshot
October 30, 2026
- New York Note - 1: JETRO’s Role in Connecting Japan with the World
October 23, 2026
- Outside the Bubble: Lunch with Pharma Delegates
September 30, 2026
- The One Mistake on Your Resume
August 31, 2026
- Why Your Brain Wants You to Stay (Even When You Want to Go)
July 31, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…